Search

Your search keyword '"alpha-Synuclein ultrastructure"' showing total 127 results

Search Constraints

Start Over You searched for: Descriptor "alpha-Synuclein ultrastructure" Remove constraint Descriptor: "alpha-Synuclein ultrastructure"
127 results on '"alpha-Synuclein ultrastructure"'

Search Results

1. Cryo-EM structures of pathogenic fibrils and their impact on neurodegenerative disease research.

2. Structures of α-synuclein filaments from human brains with Lewy pathology.

3. Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson's disease.

4. Structural and mechanistic insights into amyloid-β and α-synuclein fibril formation and polyphenol inhibitor efficacy in phospholipid bilayers.

5. The Alpha-Synuclein RT-QuIC Products Generated by the Olfactory Mucosa of Patients with Parkinson's Disease and Multiple System Atrophy Induce Inflammatory Responses in SH-SY5Y Cells.

6. Modulating α-Synuclein Liquid-Liquid Phase Separation.

7. Lipid Peroxidation Products HNE and ONE Promote and Stabilize Alpha-Synuclein Oligomers by Chemical Modifications.

8. Structural and Functional Insights into α-Synuclein Fibril Polymorphism.

9. Modulation of α-synuclein fibrillation by plant metabolites, daidzein, fisetin and scopoletin under physiological conditions.

10. Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications.

11. NMR unveils an N-terminal interaction interface on acetylated-α-synuclein monomers for recruitment to fibrils.

12. Apoptotic Neuron-Derived Histone Amyloid Fibrils Induce α-Synuclein Aggregation.

13. From Posttranslational Modifications to Disease Phenotype: A Substrate Selection Hypothesis in Neurodegenerative Diseases.

14. Seeding Propensity and Characteristics of Pathogenic αSyn Assemblies in Formalin-Fixed Human Tissue from the Enteric Nervous System, Olfactory Bulb, and Brainstem in Cases Staged for Parkinson's Disease.

15. The differential solvent exposure of N-terminal residues provides "fingerprints" of alpha-synuclein fibrillar polymorphs.

16. How epigallocatechin gallate binds and assembles oligomeric forms of human alpha-synuclein.

17. Megadalton-sized Dityrosine Aggregates of α-Synuclein Retain High Degrees of Structural Disorder and Internal Dynamics.

18. Structures of α-synuclein filaments from multiple system atrophy.

19. Parkinson's disease associated mutation E46K of α-synuclein triggers the formation of a distinct fibril structure.

20. N-Terminal Ubiquitination of Amyloidogenic Proteins Triggers Removal of Their Oligomers by the Proteasome Holoenzyme.

21. Molecular characterization of an aggregation-prone variant of alpha-synuclein used to model synucleinopathies.

22. Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.

23. Structures of fibrils formed by α-synuclein hereditary disease mutant H50Q reveal new polymorphs.

24. Examination of Adsorption Orientation of Amyloidogenic Peptides Over Nano-Gold Colloidal Particle Surfaces.

25. Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson's disease.

26. Structural Insights into α-Synuclein Fibril Polymorphism: Effects of Parkinson's Disease-Related C-Terminal Truncations.

27. Cerium oxide NPs mitigate the amyloid formation of α-synuclein and associated cytotoxicity.

28. α-synuclein interaction with zero-valent iron nanoparticles accelerates structural rearrangement into amyloid-susceptible structure with increased cytotoxic tendency.

29. Sequence- and seed-structure-dependent polymorphic fibrils of alpha-synuclein.

30. Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity.

31. Conformational ensemble of native α-synuclein in solution as determined by short-distance crosslinking constraint-guided discrete molecular dynamics simulations.

32. Cryo-Electron Microscopy Uncovers Key Residues within the Core of Alpha-Synuclein Fibrils.

33. Biochemical and morphological classification of disease-associated alpha-synuclein mutants aggregates.

34. Extracellular Alpha-Synuclein Oligomers Induce Parkin S-Nitrosylation: Relevance to Sporadic Parkinson's Disease Etiopathology.

35. Potent α-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State.

36. Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA.

37. Amyloid oligomerization of the Parkinson's disease related protein α-synuclein impacts on its curvature-membrane sensitivity.

38. Morphological Evaluation of Meta-stable Oligomers of α-Synuclein with Small-Angle Neutron Scattering.

39. Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy.

40. Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified α-synuclein oligomers.

41. Spectroscopic analysis beyond the diffraction limit.

42. FYCO1 mediates clearance of α-synuclein aggregates through a Rab7-dependent mechanism.

43. Cryo-EM structure of alpha-synuclein fibrils.

44. Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods.

45. Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced α-Synuclein Fibrillation and Cytotoxicity.

46. C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction.

47. Revolutionizing Our Understanding of Amyloidogenic Proteins by Cryo-Electron Microscopy.

48. Structural features of α-synuclein amyloid fibrils revealed by Raman spectroscopy.

49. Pleiotropic neuropathological and biochemical alterations associated with Myo5a mutation in a rat Model.

50. Comparison of α-Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors.

Catalog

Books, media, physical & digital resources